Structural and biophysical insights into targeting of claudin-4 by a synthetic antibody fragment
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Structural and biophysical insights into targeting of claudin-4 by a synthetic antibody fragment ; volume:7 ; number:1 ; day:17 ; month:6 ; year:2024 ; pages:1-16 ; date:12.2024
Communications biology ; 7, Heft 1 (17.6.2024), 1-16, 12.2024
- Urheber
-
Erramilli, Satchal K.
Dominik, Pawel K.
Ogbu, Chinemerem P.
Kossiakoff, Anthony A.
Vecchio, Alex J.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s42003-024-06437-6
- URN
-
urn:nbn:de:101:1-2408271311175.537358010632
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Erramilli, Satchal K.
- Dominik, Pawel K.
- Ogbu, Chinemerem P.
- Kossiakoff, Anthony A.
- Vecchio, Alex J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Antibody targeting of claudin-1 as a potential colorectal cancer therapy
Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinoma Using a Radiolabelled Anti-Claudin-4 Monoclonal Antibody
Synthetic Sphingolipid analogues biophysical properties and subcellular localization
Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
M cell targeting by a Claudin 4 targeting peptide can enhance mucosal IgA responses
Structural and biophysical characterization of antibody:antigen complexes of therapeutic relevance
Structural And Biophysical Characterization of Antibody-Antigen Complexes of Therapeutic Relevance
Biophysical cartography of the native and human-engineered antibody landscapes quantifies the plasticity of antibody developability
Optimal Synthetic Glycosylation of a Therapeutic Antibody
Optimal Synthetic Glycosylation of a Therapeutic Antibody
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting
Liposomes targeting the cancer cell-exposed receptor, claudin-4, for pancreatic cancer chemotherapy
Antibody targeting of claudin-1 as a potential colorectal cancer therapy
Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinoma Using a Radiolabelled Anti-Claudin-4 Monoclonal Antibody
Synthetic Sphingolipid analogues biophysical properties and subcellular localization
Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
M cell targeting by a Claudin 4 targeting peptide can enhance mucosal IgA responses
Structural and biophysical characterization of antibody:antigen complexes of therapeutic relevance
Structural And Biophysical Characterization of Antibody-Antigen Complexes of Therapeutic Relevance
Biophysical cartography of the native and human-engineered antibody landscapes quantifies the plasticity of antibody developability
Optimal Synthetic Glycosylation of a Therapeutic Antibody
Optimal Synthetic Glycosylation of a Therapeutic Antibody
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting
Liposomes targeting the cancer cell-exposed receptor, claudin-4, for pancreatic cancer chemotherapy
Antibody targeting of claudin-1 as a potential colorectal cancer therapy
Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinoma Using a Radiolabelled Anti-Claudin-4 Monoclonal Antibody
Synthetic Sphingolipid analogues biophysical properties and subcellular localization
Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
M cell targeting by a Claudin 4 targeting peptide can enhance mucosal IgA responses
Structural and biophysical characterization of antibody:antigen complexes of therapeutic relevance
Structural And Biophysical Characterization of Antibody-Antigen Complexes of Therapeutic Relevance
Biophysical cartography of the native and human-engineered antibody landscapes quantifies the plasticity of antibody developability
Optimal Synthetic Glycosylation of a Therapeutic Antibody
Optimal Synthetic Glycosylation of a Therapeutic Antibody
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting